arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

NEKTAR THERAPEUTICS

NKTR
$76.47 ▲ +2.95 (+4.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEKTAR THERAPEUTICS faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield
Revenue Growth 3.8%
Op. Margin -359.6%
ROIC -5.4%
FCF / Share $-1.79
Trailing P/E
Price / Book 2.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.86M
↑ +3.8%
Net Income Profit after all expenses
$-44.90M
↑ +11.7%
Operating Margin Operating profit as % of sales
-359.6%
↓ -183.4% 0th
FCF / Share Free cash flow per share
$-1.79
↓ -670.3%
Long-Term Debt Long-term obligations
$133.50M
↓ -1.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
3
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters